|
 To see more information on this product, please click on the title of the particular section below that you are interested in.
Company name: Ceva Animal Health Ltd Address: 90 The Broadway Chesham Buckinghamshire HP5 1EG Telephone: 01494 781510 Fax: 01494 781519 Email: cevauk@ceva.com Website: www.ceva.com
A solution for injection containing 5mg metoclopramide (as hydrochloride) per 1ml.
Symptomatic treatment of vomiting and reduced gastro-intestinal motility associated with gastritis, pyloric spasm, chronic nephritis and digestive intolerance to some drugs in dogs and cats.
Intravenous, intramuscular or subcutaneous use. 0.5 to 1 mg of metoclopramide hydrochloride per kg of body weight per day administered as either: 2.5 to 5.0 mg/10 kg (equivalent to 0.5 to 1 ml/10 kg), twice daily or 1.7 to 3.3 mg/10 kg (equivalent to 0.34 to 0.6 ml/10 kg), three times daily. Injections can be repeated with interval of 6 hours.
Do not use in cases of gastro-intestinal perforation or obstruction. Special precautions for use in animals: The dosage must be adapted in animals with renal or hepatic insufficiency (due to an increase in the risk of side effects). Avoid administration to animals with epilepsy. The dosage should be carefully observed, especially in cats and small breed dogs. Following prolonged vomiting, consideration should be given to fluid and electrolyte replacement therapy. Special precautions to be taken by the person administering the veterinary medicinal product to animals: In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician. In case of accidental exposure by spillage onto the skin or eyes, wash immediately with abundant water. If adverse effects appear, seek medical advice immediately and show the package leaflet or the label to the physician. Wash hands after administration to the animal. Adverse reactions: In some very rare cases, extrapyramidal effects (agitation, ataxia, abnormal positions and/or movements, prostration, tremors and aggression, vocalisation) have been observed after treatment of dogs and cats. These observed effects are transient and disappear when treatment is stopped. In very rare cases, allergic reactions may occur. Use during pregnancy or lactation: Laboratory studies in laboratory animals have not produced any evidence of teratogenic or foetotoxic effects. However, studies on laboratory animals are limited and the safety of the active substance has not been evaluated in the target species. The use of the product during pregnancy and lactation must be made according to the benefit/risk assessment carried out by the veterinarian. Interaction with other medicinal products and other forms of interaction: In cases of gastritis, avoid the co-administration of anticholinergic drugs (atropine) as they may counteract the effects of metoclopramide on gastrointestinal motility. In cases of simultaneous diarrhoea, there is no contra-indication to the use of anticholinergic drugs. Concurrent use of metoclopramide with neuroleptics derivated from phenothiazine (acepromazine) and butyrophenones increases the risk of extrapyramidal effects. Metoclopramide can potentiate the action of central nervous system depressants. If used concurrently, it is advised to use the lowest dosage of metoclopramide to avoid excessive sedation. Overdose: Most of the clinical signs reported after an overdosage are well known extrapyramidal side effects. In the absence of a specific antidote, it is recommended to offer a calm environment to the animal until extrapyramidal side effects disappear. Metoclopramide being rapidly metabolised and eliminated, side effects generally disappear quickly.
In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products. This veterinary medicinal product does not require any special storage conditions. Shelf life after first opening: 28 days.
POM-V
Cardboard box containing 1 vial of 10 ml.
Pharmacodynamic properties: Metoclopramide is an original orthopramide molecule. The anti-emetic action of metoclopramide is mainly due to its antagonist activity at D2 receptors in the central nervous system, preventing nausea and vomiting triggered by most stimuli. The prokinetic effect on the gastro-duodenal transit (increase in intensity and rhythm of stomach contractions and opening of the pylorus) is mediated by muscarinic activity, D2 receptor antagonist activity and 5-HT4 receptor agonist activity at the gastro-intestinal level. Pharmacokinetic particulars: Metoclopramide is rapidly and completely absorbed after parenteral administration. After subcutaneous administration to dogs and cats, maximum concentrations are obtained after 15 - 30 min. Metoclopramide is rapidly distributed into most tissues and fluids, crosses the blood-brain barrier and enters the central nervous system. Metoclopramide is metabolised by the liver. The elimination of metoclopramide is rapid, 65 % of the dose being eliminated within 24 hours in the dog, primarily by the urinary route.
Vm 15052/4052.  To see more information on this product, please click on the title of the particular section below that you are interested in.
Company name: Ceva Animal Health Ltd Address: 90 The Broadway Chesham Buckinghamshire HP5 1EG Telephone: 01494 781510 Fax: 01494 781519 Email: cevauk@ceva.com Website: www.ceva.com
A solution for oral administration containing 1mg metoclopramide (as hydrochlroride) per 1ml.
Symptomatic treatment of vomiting and reduced gastro-intestinal motility associated with gastritis, pyloric spasm, chronic nephritis and digestive intolerance to some drugs in dogs and cats.
Oral use. Administer the product directly into the mouth. 0.5 to 1 mg of metoclopramide hydrochloride per kg of body weight per day administered as either: 2.5 to 5.0 mg/10 kg (equivalent to 2.5 to 5 ml/10 kg), twice daily or 1.7 to 3.3 mg/10 kg (equivalent to 1.7 to 3.3 ml/10 kg), three times daily. Oral administrations can be repeated with interval of 6 hours.
Do not use in cases of gastro-intestinal perforation or obstruction. Special precautions for use in animals: The dosage must be adapted in animals with renal or hepatic insufficiency (due to an increase in the risk of side effects). Avoid administration to animals with epilepsy. The dosage should be carefully observed, especially in cats and small breed dogs. Following prolonged vomiting, consideration should be given to fluid and electrolyte replacement therapy. In case of vomiting after intake of the oral solution, maintain the usual interval between two administrations before administering the product again. Special precautions to be taken by the person administering the veterinary medicinal product to animals: In case of accidental ingestion, especially by children, seek medical advice immediately and show the package leaflet or the label to the physician. In case of accidental exposure by spillage onto the skin or eyes, wash immediately with abundant water. If adverse effects appear, seek medical advice immediately and show the package leaflet or the label to the physician. Wash hands after administration to the animal. Adverse reactions: In some very rare cases, extrapyramidal effects (agitation, ataxia, abnormal positions and/or movements, prostration, tremors and aggression, vocalisation) have been observed after treatment of dogs and cats. These observed effects are transient and disappear when treatment is stopped. Use during pregnancy or lactation: Laboratory studies in laboratory animals have not produced any evidence of teratogenic or foetotoxic effects. However, studies on laboratory animals are limited and the safety of the active substance has not been evaluated in the target species. The use of the product during pregnancy and lactation must be made according to the benefit/risk assessment carried out by the veterinarian. Interaction with other medicinal products and other forms of interaction: In cases of gastritis, avoid the co-administration of anticholinergic drugs (atropine) as they may counteract the effects of metoclopramide on gastrointestinal motility. In cases of simultaneous diarrhoea, there is no contra-indication to the use of anticholinergic drugs. Concurrent use of metoclopramide with neuroleptics derivated from phenothiazine (acepromazine) and butyrophenones increases the risk of extrapyramidal effects. Metoclopramide can potentiate the action of central nervous system depressants. If used concurrently, it is advised to use the lowest dosage of metoclopramide to avoid excessive sedation. Overdose: Most of the clinical signs reported after an overdosage are well known extrapyramidal side effects. In the absence of a specific antidote, it is recommended to offer a calm environment to the animal until extrapyramidal side effects disappear. Metoclopramide being rapidly metabolised and eliminated, side effects generally disappear quickly.
In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products. This veterinary medicinal product does not require any special storage conditions. Shelf life after first opening: 6 months.
POM-V
Cardboard box containing 1 vial of 125 ml.
Pharmacodynamic properties: Metoclopramide is an original orthopramide molecule. The anti-emetic action of metoclopramide is mainly due to its antagonist activity at D2 receptors in the central nervous system, preventing nausea and vomiting triggered by most stimuli. The prokinetic effect on the gastro-duodenal transit (increase in intensity and rhythm of stomach contractions and opening of the pylorus) is mediated by muscarinic activity, D2 receptor antagonist activity and 5-HT4 receptor agonist activity at the gastro-intestinal level. Pharmacokinetic particulars: Metoclopramide is rapidly and almost completely absorbed from the gastrointestinal tract following oral administration. Metoclopramide is rapidly distributed into most tissues and fluids, crosses the blood-brain barrier and enters the central nervous system. Metoclopramide is metabolised by the liver. The elimination of metoclopramide is rapid, 65 % of the dose being eliminated within 24 hours in the dog, primarily by the urinary route.
Vm 15052/4053.  | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Page loaded on Wednesday 23rd May 2012 at 3:36am |  |
| |||
 |
